Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head randomized controlled trial.

Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative areas of the pharmaceutical indus

W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more effective? In a press release, Lilly announced that in its la

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.

Eli Lilly’s obesity drug Zepbound is more effective than rival Novo Nordisk’s drug Wegovy, a head-to-head trial showed, Lilly said in a statement Wednesday. On average, Zepbound led to a superior weight loss of 20.

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.

Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters. In the study sponsored by Lilly, those on Zepbound lost an average of about 50 pounds over 72 weeks.

Eli Lilly & Co. Inc.’s stock rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound achieved an average weight loss of 20.